FROM RISK TO QUALITY: QUALITY RISK MANAGEMENT IN PHARMA TARGETING CANCER THROUGH IMMUNE MODULATION
Keywords:
Microenvironment remodeling, Cancer vaccine, cancer, chimeric antigen receptor-T cells, immune check point, immunotherapy, antibodiesAbstract
Cancer immunotherapy has emerged as a powerful strategy for treating cancer by enhancing the body’s own immune system to recognize and eliminate tumor cells. Both experimental and clinically approved therapies are being developed to improve treatment outcomes and achieve long-term tumor control. Several factors influence the effectiveness of immunotherapy, including tumor heterogeneity, gut microbiota composition, genomic variations, and epigenetic modifications. Understanding these factors helps researchers design more precise and personalized treatment approaches. A major focus of current research is the study of molecular mechanisms behind immune evasion and therapeutic resistance. Noncoding RNAs and epigenetic alterations play significant roles in regulating immune responses and tumor progression, making them promising targets for innovative intervention strategies. Various immunotherapy platforms, such as immune checkpoint inhibitors and other immune-based technologies, are being investigated and implemented in clinical practice to improve patient outcomes.
Downloads
References
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. doi:10.1016/S0092-8674(00)81683-9.
Kim K, McBride WH. Modifying radiation damage. Curr Drug Targets. 2010;11(11):1352-1365. doi:10.2174/138945010793178068.
Yanamandra U, Kumar SK. Minimal residual disease analysis in myeloma–when, why and where. Leuk Lymphoma. 2018;59(8):1772-1784. doi:10.1080/10428194.2017.1386304.
Hunter P. The fourth pillar: despite some setbacks in the clinic, immunotherapy has made notable progress toward becoming an additional therapeutic option against cancer. EMBO Rep. 2017;18(11):1889-1892. doi:10.15252/embr.201745172.
Rue R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476. doi:10.3389/fimmu.2023.1212476.
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807-821. doi:10.1038/s41423-020-0488-6.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70(4):313. doi:10.3322/caac.21660.
Ling SP, Ming LC, Dhaliwal JS, Gupta M, Adriano C, Goh KW, Hussain Z, Shaikh MF. Role of immunotherapy in the treatment of cancer: a systematic review. Cancers (Basel). 2022;14(21):5205.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013.
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807-821. doi:10.1038/s41423-020-0488-6.
Abbott M, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs. 2019;35(5):150923. doi:10.1016/j.soncn.2019.08.002.
Prasanthi G, Chandu BR, Pradeep Kumar Y, Swarnalatha D, Gopinath D. Chemical pharmacology of khat leaves. J Glob Trends Pharm Sci. 2014;5(4):2024-2029.
Busch W. Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr. 1868;5(5):137.
Kumar KR, Rao CHMM, Rao CHB, Chandra KB. RP-HPLC method development and validation for estimation of capecitabine in capsules. Int J Chem Tech Res. 2010;2(1):307-311.
Dasari V, Awen BZ, Chandu BR, Mukkanti K. Formulation and in vitro evaluation of lamivudine multiunit floating dosage forms using novel lipoidal polymers. Int J Pharma Bio Sci. 2010;1(3):1-7.
Fehleisen F. Über die Züchtung der Erysipelkokken auf künstlichem Nährboden und ihre Übertragbarkeit auf den Menschen. Dtsch Med Wochenschr. 1882;8(31):553-554.
Lizeth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat. 2017;3:250-261.
Tokarew N, Gooney J, Enders S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26-37. doi:10.1038/s41416-018-0325-1.
Barker PE, Royer HD, Riddle FH, Rehner EL. Regional location of T cell receptor gene T alpha on human chromosome 14. J Exp Med. 1985;162(1):387-392. doi:10.1084/jem.162.1.387.
Boon T. Teaching the immune system to fight cancer. Sci Am. 1993;268(3):82-89.
Nama S, Awen BZ, Chandu BR, Mukkanti K. A novel stability indicating liquid chromatographic assay for the estimation of rimonabant hydrochloride in bulk and pharmaceutical dosage forms. Afr J Pharm Sci Pharm. 2011;2:1-7.
Baoding T. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):3-20. doi:10.2174/1570163812666150602144310.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275(5304):1320-1323. doi:10.1126/science.275.5304.1320.
Rani CHU, Sumalatha G, Rao CHB, Varalakshmi TN. Alzheimer’s disease-pharmacotherapeutic interventions. Int J Pharm Chem Sci. 2013;2(2):1-8.
Sreekanth N, Awen BZ, Rao CB. A new colorimetric determination and validation of sparfloxacin based on ferric nitrate chromogen. Res J Pharm Biol Chem Sci. 2010;1(3):113-120.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
(CC BY-NC)
.